Huabei Pharma Factory To Up Output

16 July 1995

The Huabei Pharmaceutical Factory in China is planning to increase its output value to 3 billion renminbi ($361.5 million) and its profits to 800 million renminbi in 1997, reports China Foreign Trade. In the year 2002, turnover will be close to 6 billion renminbi and profit 1.6 billion renminbi, it is expected.

The company recorded turnover in 1994 of 2 billion renminbi, an increase of 33%, and profits of 250 million renminbi, ahead 61% on the previous year.

To facilitate this growth, the company is planning to expand its annual penicillin production to 3,000 tons. This move will make it one of the largest penicillin producers in the world. It will also develop new antibiotics and a vaccine for meningitis B in cooperation with Chinese medical research institutes. The Huabei Factory is the biggest producer of vitamin B12 in China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight